These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 26424350)

  • 21. PCSK9 (Proprotein convertase subtilisin/kexin type 9) inhibitors: past, present, and the future.
    Shimada YJ; Cannon CP
    Eur Heart J; 2015 Sep; 36(36):2415-24. PubMed ID: 25971287
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Cholesterol associated to low density lipoproteins (LDL) and vascular risk reduction. Proprotein convertase subtilisin/kexin type 9 (PCSK9): A new therapeutic target].
    Guijarro C; Ruilope LM
    Med Clin (Barc); 2015 Jul; 145(2):67-9. PubMed ID: 26004275
    [No Abstract]   [Full Text] [Related]  

  • 23. Hyperlipidemia and cardiovascular disease: reinforcement for 'lower is better'.
    Burkhardt R
    Curr Opin Lipidol; 2015 Oct; 26(5):468-9. PubMed ID: 26339769
    [No Abstract]   [Full Text] [Related]  

  • 24. PCSK9: is it fluoride for cardiology?
    King SB
    JACC Cardiovasc Interv; 2014 Nov; 7(11):1331-2. PubMed ID: 25459045
    [No Abstract]   [Full Text] [Related]  

  • 25. [Effective LDL cholesterol reduction for high risk patients].
    Einecke D
    MMW Fortschr Med; 2016 Apr; 158(8):84. PubMed ID: 27116175
    [No Abstract]   [Full Text] [Related]  

  • 26. Improving the care of high-risk patients: the potential of PCSK9.
    Stock J
    Atherosclerosis; 2014 Feb; 232(2):420-2. PubMed ID: 24468158
    [No Abstract]   [Full Text] [Related]  

  • 27. New therapeutic principles for Familial Hypercholesterolemia.
    Norata GD
    Clin Biochem; 2014 Jun; 47(9):756. PubMed ID: 24854692
    [No Abstract]   [Full Text] [Related]  

  • 28. Inhibition of PCSK9: is this the way forward for managing residual risk?
    Chowdhury SR; Rees A
    Curr Opin Lipidol; 2012 Oct; 23(5):509-10. PubMed ID: 22964999
    [No Abstract]   [Full Text] [Related]  

  • 29. [Hyperlipidemia. New treatment option with Evolocumab].
    Ecker-Schlipf B
    Med Monatsschr Pharm; 2014 Jul; 37(7):271-2. PubMed ID: 25065173
    [No Abstract]   [Full Text] [Related]  

  • 30. [PCSK9 monoclonal antibody inhibition: current evidence and future perspectives of lipid-lowering therapy according to the available results from the ODYSSEY program].
    Lettino M
    G Ital Cardiol (Rome); 2015 Apr; 16(4):211-6. PubMed ID: 25959756
    [No Abstract]   [Full Text] [Related]  

  • 31. Cholesterol production, accumulation, reverse transport, and excretion: opportunities for statins, PPAR-α agonists, and PCSK9 inhibitors.
    Lüscher TF
    Eur Heart J; 2015 Nov; 36(43):2965-7. PubMed ID: 26568612
    [No Abstract]   [Full Text] [Related]  

  • 32. Therapy and clinical trials.
    Sodhi N; Krasuski RA
    Curr Opin Lipidol; 2013 Jun; 24(3):281-2. PubMed ID: 23652475
    [No Abstract]   [Full Text] [Related]  

  • 33. [Anti-PCSK9 in coronary artery disease: genetic progress, therapeutic approaches].
    Abifadel M; Ghaleb Y; Elbitar S; El Khoury P; Rabès JP; Varret M; Boileau C
    Rev Prat; 2015 Mar; 65(3):326-7. PubMed ID: 26016189
    [No Abstract]   [Full Text] [Related]  

  • 34. The next generation of novel low-density lipoprotein cholesterol-lowering agents: proprotein convertase subtilisin/kexin 9 inhibitors.
    Shen L; Peng H; Xu D; Zhao S
    Pharmacol Res; 2013 Jul; 73():27-34. PubMed ID: 23578522
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PCSK9 Inhibitors: Are We on the Verge of a Breakthrough?
    Yang E
    Clin Pharmacol Ther; 2015 Dec; 98(6):590-601. PubMed ID: 26369501
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treating hypercholesterolemia - when and how].
    Vogt A
    Dtsch Med Wochenschr; 2015 Oct; 140(20):1490-3. PubMed ID: 26445250
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Antibodies in addition to statin therapy lowers LDL cholesterol].
    Bossenmayer S
    Dtsch Med Wochenschr; 2012 Sep; 137(36):1728. PubMed ID: 23281534
    [No Abstract]   [Full Text] [Related]  

  • 38. Winner by points?--LDL cholesterol as a target for therapeutic intervention.
    Tietge UJ
    Curr Opin Lipidol; 2013 Jun; 24(3):277-8. PubMed ID: 23652473
    [No Abstract]   [Full Text] [Related]  

  • 39. [PCSK9 inhibitors. A new approach for treatment of hypercholesterolemia].
    Saußele T
    Med Monatsschr Pharm; 2015 Jul; 38(7):250-7. PubMed ID: 26364362
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [In addition to atorvastatin. Innovative antibody lowers LDL around 72%].
    Einecke D
    MMW Fortschr Med; 2012 Apr; 154(7):28. PubMed ID: 22558865
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.